Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Perspective Therapeutics ( (CATX) ).
On January 9, 2026, Perspective Therapeutics reported updated interim data from its ongoing Phase 1/2a trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2‑expressing neuroendocrine tumors, based on a December 10, 2025 data cut-off and presented at the 2026 ASCO Gastrointestinal Cancers Symposium. The update showed that among 56 patients across three dose cohorts there were no dose-limiting toxicities, treatment-related discontinuations, serious renal complications, or Grade 5 events, while Grade 3 or higher treatment-emergent adverse events occurred in 37.5% of patients and serious adverse events were not attributed to the study drug. Efficacy data from both patients in Cohort 1 and 23 patients in Cohort 2 indicated that 76% of these 25 patients were alive without disease progression after roughly 13 additional weeks of follow-up versus the prior readout, with a 39% objective response rate in Cohort 2 and evidence of deepening tumor responses over time. Investigators and company executives highlighted the combination of durable anti-tumor activity and favorable tolerability at the 5.0 mCi dose, the completion of dose-limiting toxicity assessment at the higher 6.0 mCi dose, and the expanding clinical dataset as factors that strengthen the program’s profile and underpin ongoing dose optimization and future registrational planning, signaling growing clinical momentum for the company’s lead radiopharmaceutical asset and broader platform.
The most recent analyst rating on (CATX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.
Spark’s Take on CATX Stock
According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.
The score is held down primarily by very weak financial performance (large losses and significant ongoing cash burn despite modest revenue). Technicals provide some offset with improving short-term momentum versus moving averages, but longer-term trend signals remain weaker. Valuation is constrained by negative earnings (negative P/E) and no dividend support.
To see Spark’s full report on CATX stock, click here.
More about Perspective Therapeutics
Perspective Therapeutics, Inc. is a radiopharmaceutical development company focused on pioneering advanced cancer treatments using the alpha-emitting isotope 212Pb to selectively deliver radiation to tumors via specialized targeting moieties. The company is also building a theranostic platform by developing paired imaging diagnostics that use the same targets to personalize therapy, with lead programs in neuroendocrine tumors (VMT-α-NET), melanoma (VMT01), and solid tumors (PSV359) in Phase 1/2a trials in the U.S., supported by a growing network of finishing facilities enabled by its proprietary 212Pb generator.
Average Trading Volume: 1,705,561
Technical Sentiment Signal: Sell
Current Market Cap: $213.4M
For a thorough assessment of CATX stock, go to TipRanks’ Stock Analysis page.